Need Institute, Laboratory of Neurobiology for Translational Medicine, c/o Casa di Cura del Policlinico (CCP), Via Dezza 48, 20144, Milan, Italy.
Laboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, 00161, Rome, Italy.
Mol Neurodegener. 2021 Oct 18;16(1):71. doi: 10.1186/s13024-021-00479-8.
Oxidative stress (OS) is an imbalance between oxidant and antioxidant species and, together with other numerous pathological mechanisms, leads to the degeneration and death of motor neurons (MNs) in amyotrophic lateral sclerosis (ALS).
Two of the main players in the molecular and cellular response to OS are NRF2, the transcription nuclear factor erythroid 2-related factor 2, and its principal negative regulator, KEAP1, Kelch-like ECH (erythroid cell-derived protein with CNC homology)-associated protein 1. Here we first provide an overview of the structural organization, regulation, and critical role of the KEAP1-NRF2 system in counteracting OS, with a focus on its alteration in ALS. We then examine several compounds capable of promoting NRF2 activity thereby inducing cytoprotective effects, and which are currently in different stages of clinical development for many pathologies, including neurodegenerative diseases.
Although challenges associated with some of these compounds remain, important advances have been made in the development of safer and more effective drugs that could actually represent a breakthrough for fatal degenerative diseases such as ALS.
氧化应激(OS)是氧化剂和抗氧化剂之间的失衡,与其他许多病理机制一起,导致肌萎缩侧索硬化症(ALS)中的运动神经元(MNs)变性和死亡。
在分子和细胞对 OS 的反应中,两个主要参与者是 NRF2,即核转录因子红细胞 2 相关因子 2,及其主要负调节剂 KEAP1,Kelch 样 ECH(红细胞衍生蛋白 CNC 同源物)相关蛋白 1。在这里,我们首先概述 KEAP1-NRF2 系统在对抗 OS 中的结构组织、调节和关键作用,重点介绍其在 ALS 中的改变。然后,我们检查了几种能够促进 NRF2 活性从而诱导细胞保护作用的化合物,这些化合物目前处于不同的临床开发阶段,用于治疗多种疾病,包括神经退行性疾病。
尽管这些化合物中的一些仍然存在挑战,但在开发更安全、更有效的药物方面已经取得了重要进展,这些药物实际上可能成为肌萎缩侧索硬化症等致命退行性疾病的突破。